Skip to Main Content

Paper Details

Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.
Cancer Res Commun
7
2022
ALK, ALK protein, ALK-expressing, ALK-expressing neuroendocrine, ALK-expressing neuroendocrine prostate cancer, Anaplastic lymphoma kinase, RNA, advanced prostate cancer, anaplastic lymphoma kinase, localized and metastatic prostate cancer, lung cancer, lung cancers, metastatic prostate cancer, metastatic prostate cancers, neuroendocrine prostate cancer, patients, primary prostate cancer, prostate cancer, solid tumors, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Ilsa ColemanFred Hutchinson Cancer Research Center
Jin-Yih LowFred Hutchinson Cancer Research Center
Lawrence D TrueUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonDivision of Clinical Research, Fred Hutchinson Cancer Research Center
Peter S NelsonThe Brotman Baty Institute for Precision Medicine
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonThe Brotman Baty Institute for Precision Medicine
Peter S NelsonDivision of Clinical Research, Fred Hutchinson Cancer Research Center
Colm MorrisseyUniversity of Washington
Colin C PritchardUniversity of Washington
Colin C PritchardThe Brotman Baty Institute for Precision Medicine
Michael C HaffnerFred Hutchinson Cancer Research Center
Michael C HaffnerDivision of Clinical Research, Fred Hutchinson Cancer Research Center
Michael C HaffnerJohns Hopkins University School of Medicine
  • 1 - 17

Datasets

Release 1.2